Form 4: Cabaletta Bio Director Simon Mark Reports Stock Option Repricing

Director Simon Mark reports repricing of stock options at Cabaletta Bio, effective May 19, 2025.

Summary

• On May 19, 2025, Simon Mark, a director of Cabaletta Bio, Inc., reported changes in beneficial ownership due to a stock option repricing.
• The repricing, approved by the board on May 15, 2025, became effective on May 19, 2025.
• The exercise price of certain stock options was adjusted to $1.92 per share, reflecting the fair market value on the repricing date.
• The director acquired and disposed of options at different strike prices, with the total number of options held after the transactions being 66,000 at an exercise price of $1.92.
• The repriced options are subject to a retention period, where the original exercise price will be reinstated if exercised within one year of the repricing date or upon certain events like a sale event or termination due to death or disability.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The repricing could be seen as a positive sign that the company is trying to retain talent, but it also suggests the stock price may not be performing as well as hoped, hence the need for repricing.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the stock option repricing and vesting schedules.

Industry Context

Stock option repricing is a mechanism companies use to re-incentivize employees or directors when the stock price has fallen below the option's exercise price. It's a fairly common practice, especially in volatile sectors like biotechnology, to keep key personnel motivated.

Comparison to Industry Standards

• Stock option repricing is a common practice in the biotech industry, particularly for companies like Cabaletta Bio that are in the development stage and may experience stock price volatility.
• Comparable companies such as CRISPR Therapeutics or Beam Therapeutics also utilize stock options as part of their compensation packages, and may, from time to time, reprice options to maintain employee motivation.
• The specific terms of the repricing, such as the retention period, are generally in line with industry standards aimed at ensuring continued service and alignment with shareholder interests.

Stakeholder Impact

• Shareholders may view the repricing as a way to retain key personnel and align their interests with the company's long-term success.
• Employees and directors with stock options benefit from the lower exercise price, potentially increasing the value of their options.
• The repricing does not directly impact customers, suppliers, or creditors.

Key Dates

Keywords

stock options, Cabaletta Bio, Form 4, Simon Mark, repricing, director, beneficial ownership